Program
ritlecitinib
Also written as “PF-06651600”, “Ritlecitinib” and “Ritlecitinib 100 mg”.
Its studies are mostly in Alopecia Areata · Vitiligo · Arthritis, Rheumatoid · Hidradenitis Suppurativa · Chronic Urticaria, led by Pfizer.
Drug pagePF-06651600: every studyAll 46 studies of it, academic ones too, with its approvals, label and forms.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Pfizer | 428 open or running | phase 3since Nov 5, 2018 | Feb 12, 2016 | Dec 2, 2026phase 3 · NCT07029711 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.
Not listed one by one: 25 earlier studies, Feb 12, 2016 to Aug 14, 2020.
- Jun 9, 2019Named ritlecitinibINNProposed as its International Nonproprietary Name in WHO's List 121 · before, PF-06651600
- Nov 2, 2020Phase 1 study in Healthy ParticipantsNCT04634565 · 9 enrolled · China
- Sep 2, 2021Phase 1 study in Healthy ParticipantsNCT05040295 · 12 enrolled · United States
- Oct 14, 20212 phase 1 studiesNCT05097716, NCT05128058
- Oct 6, 2022Phase 3 study in Stable Nonsegmental VitiligoNCT05583526 · 607 enrolled · United States, Australia, Bulgaria and more
- Dec 6, 2022Phase 1 study in Alopecia AreataNCT05650333 · 15 enrolled · United States
- May 1, 2023Phase 1 study in Healthy VolunteersNCT05852340 · 12 enrolled · Belgium
- Oct 2, 2023Phase 3 study in Stable Nonsegmental VitiligoNCT06072183 · 1,571 enrolled · United States, Australia, Belgium and more
- Nov 30, 2023Phase 3 study in VitiligoNCT06163326 · 394 enrolled · United States, Australia, Bulgaria and more
- Dec 7, 2023Phase 1 study in Healthy VolunteersNCT06172348 · 12 enrolled · Belgium
- Apr 11, 2024Phase 1 study in Healthy VolunteersNCT06369454 · 12 enrolled · United States
- Mar 7, 2025Phase 3 study in Alopecia AreataNCT06873945 · 674 planned · United States, Canada, China and more
- Jun 11, 20252 phase 3 studies in Alopecia AreataNCT07029828, NCT07029711
- Oct 20, 20252 phase 2 studiesNCT07219615, NCT07228390
- Jul 24, 2026Phase 3 study in Alopecia AreataNCT07733765 · 336 planned · United States, Canada, China and more
Ahead
- Dec 2, 2026Primary completion: phase 3 study in Alopecia AreataNCT07029711
- Dec 8, 2026Primary completion: phase 2 study in Hidradenitis SuppurativaNCT07228390
- Dec 25, 2026Primary completion: phase 2 study in Chronic UrticariaNCT07219615
- Mar 31, 2027Primary completion: phase 3 study in VitiligoNCT06163326
TargetBeta
“An orally available small-molecule inhibitor of tyrosine-protein kinase JAK3 (Janus kinase 3; JAK3) ”NCIt, by rule
“Tyrosine-protein kinase JAK3 inhibitor; TEC family kinase inhibitor; Tyrosine-protein kinase JAK3 inhibitor; TEC family kinase inhibitor”ChEMBL 37, by rule
Studies
All 42 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07733765Alopecia Areata · United States, Canada, China and more | 3 | Recruiting | Apr 26, 2028 | 336 |
| NCT07228390Hidradenitis Suppurativa · United States, Canada, Germany and more | 2 | Active, not recruiting | Dec 8, 2026 | 128 |
| NCT07219615Chronic Urticaria · United States, Bulgaria, Canada and more | 2 | Recruiting | Dec 25, 2026 | 200 |
| NCT07029828Alopecia Areata · United States, China, Czechia and more | 3 | Recruiting | Jun 26, 2030 | 140 |
| NCT07029711Alopecia Areata · United States, China, Czechia and more | 3 | Active, not recruiting | Dec 2, 2026 | 208 |
| NCT06873945Alopecia Areata · United States, Canada, China and more | 3 | Recruiting | Mar 19, 2028 | 674 |
| NCT06369454Healthy Volunteers · United States | 1 | Completed | Jul 31, 2024 | 12 |
| NCT06172348Healthy Volunteers · Belgium | 1 | Completed | Mar 28, 2024 | 12 |
| NCT06163326Vitiligo · United States, Australia, Bulgaria and more | 3 | Active, not recruiting | Mar 31, 2027 | 394 |
| NCT06072183Stable Nonsegmental Vitiligo · United States, Australia, Belgium and more | 3 | Active, not recruiting | Jul 30, 2027 | 1,571 |
| NCT05852340Healthy Volunteers · Belgium | 1 | Completed | Jun 15, 2023 | 12 |
| NCT05650333Alopecia Areata · United States | 1 | Completed | Aug 11, 2023 | 15 |
| NCT05583526Stable Nonsegmental Vitiligo · United States, Australia, Bulgaria and more | 3 | Completed | Feb 5, 2026 | 607 |
| NCT05128058Healthy · United States | 1 | Completed | Jan 14, 2022 | 16 |
| NCT05097716Healthy Volunteers · United States | 1 | Completed | Jan 10, 2022 | 12 |
| NCT05040295Healthy Participants · United States | 1 | Completed | Nov 19, 2021 | 12 |
| NCT04634565Healthy Participants · China | 1 | Completed | Nov 19, 2020 | 9 |
| NCT04517864Alopecia Areata · United States, Australia, Canada and more | 2 | Terminated | Jan 4, 2022 | 71 |
| NCT04413617Arthritis, Rheumatoid · Bulgaria, Canada, Chile and more | 2 | Completed | Feb 7, 2022 | 460 |
| NCT04390776Healthy Participants · United States | 1 | Completed | Jul 19, 2021 | 164 |
| NCT04355845Healthy Volunteers · United States | 1 | Completed | Aug 10, 2020 | 10 |
| NCT04266509Healthy Volunteers · Belgium | 1 | Completed | Sep 10, 2020 | 12 |
| NCT04092595Healthy Volunteers · Belgium | 1 | Completed | Jan 15, 2020 | 12 |
| NCT04037865Renal Insufficiency · United States | 1 | Terminated | Mar 31, 2020 | 8 |
| NCT04018274Healthy · United States | 1 | Completed | Oct 16, 2019 | 29 |
| NCT04016077Hepatic Impairment · United States | 1 | Completed | Mar 5, 2020 | 18 |
| NCT04006457Alopecia Areata · United States, Argentina, Australia and more | 3 | Completed | Jun 25, 2024 | 1,057 |
| NCT04004663Healthy Volunteers · Belgium | 1 | Completed | Oct 11, 2019 | 12 |
| NCT03929510Healthy Volunteers · Netherlands | 1 | Completed | Jul 5, 2019 | 6 |
| NCT03916393Healthy Participants · Belgium | 1 | Completed | May 10, 2019 | 10 |
| NCT03827668Healthy · United States | 1 | Completed | Apr 29, 2019 | 15 |
| NCT03821493Healthy Participants · Belgium | 1 | Completed | Apr 6, 2019 | 12 |
| NCT03762928Healthy Subjects · United States | 1 | Completed | Jan 27, 2019 | 12 |
| NCT03732807Alopecia Areata · United States, Argentina, Australia and more | 3 | Completed | Dec 31, 2020 | 718 |
| NCT03715829Active Non-segmental Vitiligo · United States, Australia, Belgium and more | 2 | Completed | Feb 5, 2021 | 366 |
| NCT03608241Healthy Females · United States | 1 | Completed | Nov 23, 2018 | 12 |
| NCT03395184Crohn Disease · United States, Australia, Austria and more | 2 | Completed | Oct 19, 2023 | 244 |
| NCT03232905Healthy · Belgium | 1 | Completed | Oct 27, 2017 | 6 |
| NCT02974868Alopecia Areata · United States, Australia, Canada | 2 | Completed | May 15, 2019 | 142 |
| NCT02969044Arthritis, Rheumatoid · United States, Bulgaria, Czechia and more | 2 | Completed | Dec 12, 2017 | 70 |
| NCT02958865Colitis, Ulcerative · United States, Austria, Bulgaria and more | 2 | Completed | May 10, 2021 | 319 |
| NCT02684760Inflammatory Bowel Diseases · Belgium | 1 | Completed | May 2016 | 14 |
How it is read
Names in the registry
- “PF-06651600”, 25 entries
- “Ritlecitinib”, 9 entries
- “Ritlecitinib 100 mg”, 4 entries
- “Ritlecitinib 50 mg”, 4 entries
- “ritlecitinib”, 3 entries
Conditions, from the studies’ own filings
- Alopecia Areata, 9 studies
- Vitiligo, 4 studies
- Arthritis, Rheumatoid, 2 studies
- Hidradenitis Suppurativa, 1 study
- Chronic Urticaria, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.